{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:30Z","timestamp":1787017110496,"version":"build-2736575974"},"reference-count":53,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,12,16]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/purpose<\/jats:title>\n                    <jats:p>The manifestations of uveitis are well established in axial spondyloarthritis (ax-SpA), but not in psoriatic arthritis (PsA). We aimed to assess, in a large unselected series of PsA: (A) the frequency and clinical features of uveitis; (B) its association with PsA activity, the impact of disease and functional disability, and (C) its relationship with the biological treatment. In addition, a literature review was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective longitudinal study of PsA patients from a single referral hospital. PsA was classified according to the CASPAR criteria, and uveitis was diagnosed by experienced ophthalmologists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We studied 406 patients with PsA (46.3\u00b112.3 years). Uveitis was observed in 20 (4.9%). Uveitis was acute in all cases, anterior (80%), unilateral (80%) and recurrent (50%). Patients with uveitis had a higher prevalence of HLA-B27 (45% vs 7.5%, p&lt;0.0001), sacroiliitis on MRI (25% vs 8.3% p=0.027), ocular surface pathology (10% vs 0.8%, p=0.021), and median PsA impact of Disease Score (5.9 (2.1\u20136.8) vs 1.25 (0.0\u20133.0), p=0.001) and Bath Ankylosing Spondylitis Functional Index (4 (1.6\u20135) vs 1.0 (0.0\u20133.5), p=0.01) than patients without uveitis.<\/jats:p>\n                    <jats:p>The exposure adjusted incidence rate (episodes\/100 patients-year) of uveitis before versus after biological treatment decreased with anti-TNF\u03b1 monoclonal antibodies (56.3 vs 9.4) and increased with etanercept (ETN) (6.03 vs 24.2) and secukinumab (SECU) (0 vs 50) (including only one patient treated in the last two cases).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of uveitis in patients with PsA was about 5%. The pattern was similar to that observed in ax-SpA. Uveitis was associated with a worse quality of life and greater functional disability. The uveitis exposure adjusted incidence rate decreased with anti-TNF\u03b1 monoclonal antibodies and increased with ETN and SECU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002781","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T09:49:53Z","timestamp":1673516993000},"page":"e002781","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Uveitis in psoriatic arthritis: study of 406 patients in a single university center and literature review"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4724-389X","authenticated-orcid":false,"given":"Ana","family":"De Vicente Delm\u00e1s","sequence":"first","affiliation":[{"name":"Rheumatology, Hospital General Santa Mar\u00eda del Puerto, El Puerto de Santa Mar\u00eda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Sanchez-Bilbao","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Calvo-R\u00edo","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2137-3255","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Sierrallana y Tres Mares, Torrelavega, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Herrero-Morant","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gal\u00edndez-Agirregoikoa","sequence":"additional","affiliation":[{"name":"Rheumatology, Basurto University Hospital, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7108-8519","authenticated-orcid":false,"given":"I\u00f1igo","family":"Gonzalez-Mazon","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Barroso-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Puerta del Mar, C\u00e1diz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-0283","authenticated-orcid":false,"given":"Natalia","family":"Palmou-Fontana","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7406","authenticated-orcid":false,"given":"Miguel A","family":"Gonzalez-Gay","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-8847","authenticated-orcid":false,"given":"Jos\u00e9 L","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Medicine and Psychiatry.University of Cantabria. Internal Medicine Division, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"2025090313074546000_9.1.e002781.1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.18240\/ijo.2020.04.19","article-title":"Association between uveitis and psoriatic disease: a systematic review and meta-analysis based on the evidence from cohort studies","volume":"13","author":"Li","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"2025090313074546000_9.1.e002781.2","doi-asserted-by":"crossref","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: review and update","volume":"214","author":"P\u00e9rez-Chada","year":"2020","journal-title":"Clin Immunol"},{"key":"2025090313074546000_9.1.e002781.3","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.40568","article-title":"The eyes have it: a rheumatologist's view of uveitis","volume":"70","author":"Rosenbaum","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090313074546000_9.1.e002781.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0403-2"},{"key":"2025090313074546000_9.1.e002781.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.35.4.354"},{"key":"2025090313074546000_9.1.e002781.6","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.28798"},{"key":"2025090313074546000_9.1.e002781.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0203-7"},{"key":"2025090313074546000_9.1.e002781.8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/08820538.2016.1170161","article-title":"Psoriasis and psoriatic Arthritis-Related uveitis: different Ophthalmological manifestations and ocular inflammation features","volume":"32","author":"Abbouda","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"2025090313074546000_9.1.e002781.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.1.67"},{"key":"2025090313074546000_9.1.e002781.10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1590\/S0365-05962012000600009","article-title":"Psoriasis and uveitis: a literature review","volume":"87","author":"Fraga","year":"2012","journal-title":"An Bras Dermatol"},{"key":"2025090313074546000_9.1.e002781.11","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","article-title":"Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis","volume":"59","author":"Pittam","year":"2020","journal-title":"Rheumatology"},{"key":"2025090313074546000_9.1.e002781.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/9308341","article-title":"Psoriasis and risk of uveitis: a systematic review and meta-analysis","volume":"2020","author":"Chaiyabutr","year":"2020","journal-title":"Biomed Res Int"},{"key":"2025090313074546000_9.1.e002781.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.08.053"},{"key":"2025090313074546000_9.1.e002781.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203582"},{"key":"2025090313074546000_9.1.e002781.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.2.128"},{"key":"2025090313074546000_9.1.e002781.16","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309499"},{"key":"2025090313074546000_9.1.e002781.17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/art.38873","article-title":"Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis","volume":"67","author":"Robinson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313074546000_9.1.e002781.18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/BOR.0000000000000619","article-title":"The use of biologics for uveitis associated with spondyloarthritis","volume":"31","author":"Arepalli","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2025090313074546000_9.1.e002781.19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/1744666X.2020.1685382","article-title":"Tnf-Alpha inhibitors for the six treatment targets of psoriatic arthritis","volume":"15","author":"Lubrano","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090313074546000_9.1.e002781.20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.22336\/rjo.2018.17","article-title":"Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?","volume":"62","author":"Mitulescu","year":"2018","journal-title":"Rom J Ophthalmol"},{"key":"2025090313074546000_9.1.e002781.21","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.866038"},{"key":"2025090313074546000_9.1.e002781.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.05.007"},{"key":"2025090313074546000_9.1.e002781.23","doi-asserted-by":"crossref","first-page":"108390","DOI":"10.1016\/j.clim.2020.108390","article-title":"Challenges in the clinical diagnosis of psoriatic arthritis","volume":"214","author":"Rida","year":"2020","journal-title":"Clin Immunol"},{"key":"2025090313074546000_9.1.e002781.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2025090313074546000_9.1.e002781.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)74235-7"},{"key":"2025090313074546000_9.1.e002781.26","first-page":"S47","article-title":"Measures of symptoms and disease status in ankylosing spondylitis: ankylosing spondylitis disease activity score (ASDAS), ankylosing spondylitis quality of life scale (ASQoL), Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), Bath ankylosing spondylitis global score (BAS-G), Bath ankylosing spondylitis Metrology index (BASMI), Dougados functional index (DFI), and health assessment questionnaire for the Spondylarthropathies (HAQ-S)","volume":"63 Suppl 11","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2025090313074546000_9.1.e002781.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025090313074546000_9.1.e002781.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"2025090313074546000_9.1.e002781.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.012"},{"key":"2025090313074546000_9.1.e002781.30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10792-019-01183-9","article-title":"Ocular manifestations of rheumatic diseases","volume":"40","author":"Kemeny-Beke","year":"2020","journal-title":"Int Ophthalmol"},{"key":"2025090313074546000_9.1.e002781.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.08.002"},{"key":"2025090313074546000_9.1.e002781.32","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/rheumatology\/kex057","article-title":"Ocular involvement in patients with spondyloarthritis","volume":"56","author":"Bacchiega","year":"2017","journal-title":"Rheumatology"},{"key":"2025090313074546000_9.1.e002781.33","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-015-0536-x","article-title":"And spondyloarthritis: more than meets the eye","volume":"17","author":"Khan","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313074546000_9.1.e002781.34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11926-012-0267-1","article-title":"Uveitis in seronegative arthritis","volume":"14","author":"Wendling","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313074546000_9.1.e002781.35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075754"},{"key":"2025090313074546000_9.1.e002781.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"2025090313074546000_9.1.e002781.37","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21688"},{"key":"2025090313074546000_9.1.e002781.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.33415"},{"key":"2025090313074546000_9.1.e002781.39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09273948.2016.1185527","article-title":"Clinical spectrum of HLA-B27-associated ocular inflammation","volume":"25","author":"Pathanapitoon","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"2025090313074546000_9.1.e002781.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2960-8"},{"key":"2025090313074546000_9.1.e002781.41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1756-185X.2012.01736.x","article-title":"Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study","volume":"15","author":"Niccoli","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"2025090313074546000_9.1.e002781.42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.berh.2019.01.002","article-title":"Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis","volume":"32","author":"Liew","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025090313074546000_9.1.e002781.43","doi-asserted-by":"crossref","DOI":"10.3390\/medicina56080415","article-title":"The number of traditional cardiovascular risk factors is independently correlated with disease activity in patients with psoriatic arthritis","volume":"56","author":"Ferraz-Amaro","year":"2020","journal-title":"Medicina"},{"key":"2025090313074546000_9.1.e002781.44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313074546000_9.1.e002781.45","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211003803","article-title":"Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study","volume":"13","author":"van der Horst-Bruinsma","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090313074546000_9.1.e002781.46","doi-asserted-by":"crossref","first-page":"700.1","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090313074546000_9.1.e002781.47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA):updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313074546000_9.1.e002781.48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210931"},{"key":"2025090313074546000_9.1.e002781.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.05.005"},{"key":"2025090313074546000_9.1.e002781.50","doi-asserted-by":"publisher","DOI":"10.1002\/art.22918"},{"key":"2025090313074546000_9.1.e002781.51","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11139","article-title":"Incidence of uveitis in Secukinumab-treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies","volume":"2","author":"Deodhar","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025090313074546000_9.1.e002781.52","unstructured":"Roche D , Badard M , Boyer L . and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis. Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials [abstract]. Arthritis Rheumatol 2019;71.doi:"},{"key":"2025090313074546000_9.1.e002781.53","doi-asserted-by":"crossref","first-page":"9.1","DOI":"10.1136\/annrheumdis-2020-eular.234","article-title":"OP0014\u2005COMPARISON OF ANTERIOR UVEITIS OCCURRENCE DURING TREATMENT WITH SECUKINUMAB, ADALIMUMAB, INFLIXIMAB AND ETANERCEPT IN SPONDYLOARTHRITIS","volume":"79","author":"Lindstr\u00f6m","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:07:57Z","timestamp":1756930077000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,12]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/rmdopen-2022-002781"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002781","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}